Comparative Pharmacology
Head-to-head clinical analysis: MELOXICAM versus NAPRELAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELOXICAM versus NAPRELAN.
MELOXICAM vs NAPRELAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and inflammation.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates pain, inflammation, and fever.
7.5-15 mg orally once daily; maximum 15 mg/day. For osteoarthritis, rheumatoid arthritis: 7.5 mg once daily, may increase to 15 mg/day if needed. For juvenile rheumatoid arthritis, weight-based dosing.
750 mg to 1000 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life: 15–20 hours. Clinical context: Allows once-daily dosing; steady-state achieved in 3–5 days.
Clinical Note
moderateMeloxicam + Gatifloxacin
"Meloxicam may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateMeloxicam + Rosoxacin
"Meloxicam may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateMeloxicam + Levofloxacin
"Meloxicam may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateMeloxicam + Trovafloxacin
"Meloxicam may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life: 10-20 hours; context: allows twice-daily or once-daily dosing for chronic pain or inflammation.
Approximately 50% renal excretion of unchanged drug and metabolites; 50% fecal excretion via bile. Renal elimination accounts for ~5% unchanged meloxicam; the remainder as metabolites (primarily oxidative and glucuronide conjugates).
Renal: 50-60% as metabolites and conjugates; biliary/fecal: ~5%; remainder uncharacterized.
Category D/X
Category C
NSAID
NSAID